The design and development of a drug is a very long process that generally takes many years of research. The laborious and expensive drug development pipeline, still characterized by a low success rate, requires several steps, including target identification, hit generation, hit-to-lead optimization, and preclinical/clinical evaluation. However, assessment of preclinical safety and potential efficacy in clinical trials are the Achilles’ heels of the study, as the most candidates halt their race to market due to pharmacokinetic (PK) issues. The hit-to-lead optimization, which represents a crucial step in the early drug discovery process, aims at improving the drug-likeness by modifying physicochemical properties, improving pharmacokinetic/pharmacodynamic (PD) profiles, and reducing off-target activities. Increasingly, lead optimization may benefit from the support of in silico studies for target identification and validation, as well as for Quantitative Estimation of Drug-Likeness (QED) predictions (Bickerton et al., 2012) and the adsorption, distribution, metabolism, excretion, and toxicity (ADMET) score (Guan et al., 2019) by adopting machine learning algorithms based on different molecular descriptors which allow to discriminate drug-like and non-drug-like compounds with high accuracy of 90%. Artificial Intelligence and -omic sciences can speed up the drug discovery process, but they should be combined with innovation, effectiveness, and efficiency for the construction of new organic molecules, always trying to follow the twelve principles of Green Chemistry (Anastas and Eghbali, 2010). However, daily, academia and large pharmaceutical companies have to deal with two major problems in their laboratory routines: high quantities of hazardous chemical waste in the production and purification processes and long reaction times. The environmentally friendly synthetic approaches, including mechanosynthesis, sonosynthesis, electrosynthesis, and microwave assisted organic synthesis (MAOS), and combinatorial and automated synthetic methods allow to overcome these issues, enabling greener chemistry in a shorter timescale. For example, MAOS in the synthesis of organic compounds, polymers, inorganic materials, and nanomaterials allows to obtain the desired molecules selectively, in higher yields, and in a few minutes compared to conventional reflux heating, by monitoring parameters like temperature, pressure, and ramping of temperature, and choosing not flammable or corrosive and non-volatile media solvents (Raimondi et al., 2019).
Heteroatomic fragments and heterocyclic scaffolds are very common in molecules with therapeutic properties because they aid to modify physicochemical properties and accomplish the best ADME/Tox results for drug candidates. In fact, heterocycles are usually used to optimize potency and selectivity through bioisosteric substitution of a variety of functional groups (Raimondi et al., 2012; Cascioferro et al., 2016; Barreca et al., 2021; Cruz, 2022). Moreover, more than 75% of the heterocyclic derivatives currently in clinical use contain at least two heteroatoms (Maggio et al., 2012; Sharma et al., 2020). According to a recent analysis conducted by de la Torre and Albericio (2022), in 2021, among the 36 new chemical entities (NCEs) approved by the US Food and Drug Administration (FDA), almost 50% are aromatic nitrogen heterocycles; and, from April 2020 to February 2022, triazole, tetrazoles, imidazoles/benzimidazoles, pyrimidines, and quinolines were the most frequently used building blocks in medicinal chemistry programs (Ebenezer et al., 2022). Also, statistical data reveals that more than 85% of bioactive compounds contain at least one nitrogen atom in their structure (Heravi and Zadsirjan, 2020; Barreca et al., 2022). Natural plant-, microorganism-, and animal-based biomolecules represent an important source of inspiration in the 21st century. About a quarter of all FDA-approved drugs are plant based, e.g., the strong opiate morphine mostly used for pain medication. Whilst about a third of FDA-approved drugs over the past 20 years are based on natural products or their derivatives, including antibiotics such as tetracycline from Streptomyces aureofaciens, artemisinin from Artemisia afra, doxorubicin from Streptomyces peucetius, cyclosporine from Tolypocladium inflatum, and so on (Thomford et al., 2018; Raimondi et al., 2020).
The Research Topic “Emerging Heterocycles as Bioactive Compounds” encompasses a Research Topic of one review and three original research articles focusing on the synthesis and biological evaluation of novel bioactive compounds.
Inspired by the biological properties of natural products (NPs), Huang et al., report the design, synthesis and the biological evaluation of a series of natural product-derived compounds which integrate three different moieties: L-menthone, pyrimidine, and urea. L-Menthone is one of the main components of the essential oil of Mentha Canadensis L. and can be prepared by oxidation of menthol. On the other hands, pyrimidine and urea compounds have received considerable attention in synthetic chemistry due to their diverse bioactivities. The new compounds have the potential to alter the overactivation of PI3K/Akt/mTOR cell grown signalling pathway in cancer. The in vitro antitumor activity was investigated against four cancer cell lines, including Hela, MGC-803, MCF-7, and A549. Cell cycle, cell apoptosis and western blot analyses confirmed the mechanism of action predicted by network pharmacology analysis and molecular docking.
The second article by Khandazhinskaya et al. describes the synthesis of a new series of 5′-norcarbocyclic fleximers bearing an artificial sugar fragment with a pyrazole-containing heterocyclic base, and the inhibitory properties in respect to purine nucleoside phosphorylase (PNP). Today, fleximer analogues of nucleosides are in the crossroad of heterocyclic and nucleoside chemistry, and this class of compounds is very promising because of a wide spectrum of biological activities. Specifically, the design with the fleximer aza/deazapurine bases can ensure additional conformational freedom in order to maximize structural interactions in the active site of the target enzyme while maintaining the structural similarity with a normal nucleoside substrate. Thus, helping with better understanding of enzyme specificity. The new compounds interact with the active site of the PNP of E. coli like natural heterocyclic bases, showing weak, non-competitive inhibitory activity.
Pantetheinase is an enzyme that in humans is encoded by the VNN1 gene. The main effect of vanin-1/VNN1 is related to its pantetheinase sulfhydrylase activity, which can hydrolyze pantetheine into pantothenic acid and cysteamine. The enzymatic activity of vanin-1/VNN1 has been found to be essential in the development of many diseases. Wang et al. used fluorescent and bioluminescent probes to establish a series of visual screening methods and evaluate the inhibitory activity of a number of novel VNN1 inhibitors with different backbones. The authors demonstrated that VNN1 has a role of a pro-inflammatory agent during the onset of inflammatory bowel diseases (IBDs). Thus, the development of VNN1 inhibitors can provide a new avenue for effective IBD treatment to alleviate suffering.
Finally, the review article by Tamatam et al. describes methodologies and mechanistic insights for the synthesis of nitrogen-containing heterocyclic quinazolines via transition metal-catalysed reactions, paying attention to the advantages, limitations, and future perspectives of quinazoline synthesis via such reactions.
In conclusion, this Research Topic of articles demonstrates the importance of the heterocycles of natural or synthetic origin in molecules with therapeutic properties and recent advances in the preparation of the quinazoline scaffold.
Statements
Author contributions
This Editorial was cooperatively prepared by GLP, RH, VS, MB, IS, and MVR. The authors approved the final submitted version.
Acknowledgments
We thank the authors, reviewers and editors who helped make this Research Topic possible.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AnastasP.EghbaliE. (2010). Green chemistry: Principles and practice. Chem. Soc. Rev.39, 301–312. 10.1039/B918763B
2
BarrecaM.SpanòV.RaimondiM. V.TarantelliC.SprianoF.BertoniF.et al (2021). Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. Eur. J. Med. Chem.1, 100004. 1-9. 10.1016/j.ejmcr.2021.100004
3
BarrecaM.SpanòV.RoccaR.BivacquaR.AbelA. C.MarucaA.et al (2022). Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas. Eur. J. Med. Chem.243, 114744. 1-25. 10.1016/j.ejmech.2022.114744
4
BickertonG. R.PaoliniG. V.BesnardJ.MuresanS.HopkinsA. L. (2012). Quantifying the chemical beauty of drugs. Nat. Chem.4 (2), 90–98. 10.1038/nchem.1243
5
CascioferroS.MaggioB.RaffaD.RaimondiM. V.CusimanoM. G.SchillaciD.et al (2016). Synthesis and biofilm formation reduction of pyrazole-4-carboxamide derivatives in some Staphylococcus aureus strains. Eur. J. Med. Chem.123, 58–68. 10.1016/j.ejmech.2016.07.030
6
CruzN. (2022). Drug design: Influence of heterocyclic structure as bioisosteres. J. Med. Org. Chem.5 (6), 113–117. 10.37532/jmoc.2022
7
de la TorreB. G.AlbericioF. (2022). The pharmaceutical industry in 2021. An analysis of FDA drug approvals from the perspective of molecules. Molecules27 (3), 1075. 1-15. 10.3390/molecules27031075
8
EbenezerO.JordaanM. A.CarenaG.BonoT.ShapiM.TuszynskiJ. A. (2022). An overview of the biological evaluation of selected nitrogen-containing heterocycle medicinal chemistry compounds. Int. J. Mol. Sci.23 (15), 8117. 1-42. 10.3390/ijms23158117
9
GuanL.YangH.CaiY.SunL.DiP.LiW.et al (2019). ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness. Med. Chem. Commun.10, 148–157. 10.1039/C8MD00472B
10
HeraviM. M.ZadsirjanV. (2020). Prescribed drugs containing nitrogen heterocycles: An overview. RSC Adv.10, 44247–44311. 10.1039/D0RA09198G
11
MaggioB.RaffaD.RaimondiM. V.PlesciaF.TrincavelliM. L.MartiniC.et al (2012). Synthesis, benzodiazepine receptor binding and molecular modelling of isochromeno[4,3-c]pyrazol-5(1H)-one derivatives. Eur. J. Med. Chem.54, 709–720. 10.1016/j.ejmech.2012.06.028
12
RaimondiM. V.ListroR.CusimanoM. G.La FrancaM.FaddettaT.GalloG.et al (2019). Pyrrolomycins as antimicrobial agents. Microwave-assisted organic synthesis and insights into their antimicrobial mechanism of action. Bioorg Med Chem27 (5), 721–728. 10.1016/j.bmc.2019.01.010
13
RaimondiM. V.MaggioB.RaffaD.PlesciaF.CascioferroS.CancemiG.et al (2012). Synthesis and anti-staphylococcal activity of new 4-diazopyrazole derivatives. Eur. J. Med. Chem.58, 64–71. 10.1016/j.ejmech.2012.09.041
14
RaimondiM. V.PresentatoA.Li PetriG.ButtacavoliM.RibaudoA.De CaroV.et al (2020). New synthetic nitro-pyrrolomycins as promising antibacterial and anticancer agents. Antibiotics9 (6), 292. 1-18. 10.3390/antibiotics9060292
15
SharmaS.KumarD.SinghG.MongaV.KumarB. (2020). Recent advancements in the development of heterocyclic anti-inflammatory agents. Eur. J. Med. Chem.200, 112438. 1–25. 10.1016/j.ejmech.2020.112438
16
ThomfordN. E.SenthebaneD. A.RoweA.MunroD.SeeleP.MaroyiA.et al (2018). Natural products for drug discovery in the 21st century: Innovations for novel drug discovery. Int. J. Mol. Sci.19 (6), 1578. 1–29. 10.3390/ijms19061578
Summary
Keywords
heterocycles, new chemical entities, natural products, purine nucleoside phosphorylase, pantetheinase sulfhydrylase activity, quinazoline
Citation
Li Petri G, Holl R, Spanò V, Barreca M, Sardo I and Raimondi MV (2023) Editorial: Emerging heterocycles as bioactive compounds. Front. Chem. 11:1202192. doi: 10.3389/fchem.2023.1202192
Received
07 April 2023
Accepted
17 April 2023
Published
26 April 2023
Volume
11 - 2023
Edited and reviewed by
Anton V. Dolzhenko, Monash University, Australia
Updates
Copyright
© 2023 Li Petri, Holl, Spanò, Barreca, Sardo and Raimondi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria Valeria Raimondi, mariavaleria.raimondi@unipa.it; Virginia Spanò, virginia.spano@unipa.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.